Insmed Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.7%projected annual EPS growth
Analyst Coverage
22analysts covering
FY Revenue (est.)
$1.8Bnext fiscal year
FY EPS (est.)
-$1.55next fiscal year
Monitoring Framework
Key Performance Indicators
BRINSUPRI (brensocatib) Annual Revenue Annually172.7MTarget: At least $1.0 billion
ARIKAYCE Annual Revenue Annually433.8MTarget: $450 million to $470 million
Total Company Annual Revenue Annually606.4MTarget: $1.45 billion to $1.47 billion
Watch Items
- Regulatory decisions for BRINSUPRI (brensocatib) in Japan and the United KingdomTrigger: Approval or rejection by regulatory authorities in 2026Action: Assess commercial launch timelines and update international revenue projections
- Phase 2b CEDAR study of brensocatib in patients with hidradenitis suppurativa (HS)Trigger: Topline data readout in Q2 2026Action: Evaluate clinical efficacy and safety profile to determine pipeline expansion potential
- Phase 3 ENCORE trial of ARIKAYCE in newly diagnosed or recurrent MAC lung diseaseTrigger: Topline data readout in March or April 2026Action: Analyze potential to expand ARIKAYCE's addressable patient population to front-line therapy
Research as of 2 Sep 2026